The Promise -or Peril- of Personalized Medicine

23 FDA-approved drugs — mostly for treating cancer — are being marketed with tests designed to identify “biomarkers,” or genetic signatures indicating which patients are most likely to respond.

These drugs now account for more than $26 billion in revenues on an annualized basis.  [Article]

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s